Clinical trials: Open Bite
Acute Ischemic Stroke
Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
The HOPE-MeVO study aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke due to medium vessel occlusion presenting 4.5 to 24 hours after stroke…
- Trial name
- HOPE-MeVO (NCT07776873)
- Testing
- Recombinant Human Prourokinase for Injection (rhPro-UK), Standard medical treatment (SMT)
- Where
- China
- Volunteers
- 616 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Large Vessel Occlusion, Acute Ischemic Stroke
Intracranial Thrombosis Aspiration Catheter for Recanalization in Acute Ischemic Stroke Therapy (RECOVER)
This study is a prospective, multi-center, open-label, end-point blinded, randomized, parallel positive control, non-inferiority clinical trial, with a purpose to evaluate the safety and efficacy of Hemo Jirui intracranial…
- Conditions
- Large Vessel Occlusion, Acute Ischemic Stroke, Cerebrovascular Disorders
- Trial name
- NCT03753061
- Testing
- Aspiration Catheter, Solitaire FR
- Where
- 23 sites in China
- Volunteers
- 204 people
- Sponsor
- Ministry of Science and Technology of the People´s Republic of China
Graft Patency
Study of Feasibility for Surgical Patients Undergoing Heart Surgery With the Mammary Arteries: Reviewing Infection, Occlusion Rates and Pain Assessments.
The Pilot study for the COMFORT Trial is a single centre trial to determine the feasibility of the full COMFORT Trial. The main COMFORT Trial will be a multi-centre trial to investigate the coronary artery bypass grafting…
- Trial name
- COMFORT pilot (NCT07599553)
- Testing
- Skeletonized vs non-skeletonized harvesting of the left internal mammary artery
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Stroke Acute, Thrombectomy
Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography
The goal of this clinical trial is to investigate if endovascular treatment (EVT) can effectively treat patients with large vessel occlusion (LVO) who present beyond the typical 24-hour window after symptom onset.
- Conditions
- Stroke Acute, Thrombectomy, Medical Treatment, Large Vessel Occlusion
- Trial name
- NCT06654375
- Testing
- Endovascular Thrombectomy
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Tianjin Huanhu Hospital
Ischemic Stroke
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain.
- Trial name
- LEAST (NCT07511543)
- Testing
- Semaglutide
- Volunteers
- 100 people
- Sponsor
- Population Health Research Institute
Peripheral Arterial Disease (PAD)
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries.
- Trial name
- NCT00707876
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).
- Trial name
- ANDROID (NCT01724554)
- Testing
- Intravitreal Aflibercept Injection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ophthalmic Consultants of Boston
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion
This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study.
- Trial name
- FALCON (NCT01809236)
- Testing
- Conbercept
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes
The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in BioFlo implanted port catheters.
- Trial name
- NCT02923830
- Testing
- Heparinized saline catheter flush, Saline-only catheter flush
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- TriHealth Inc.
Thrombosis, Venous Thrombosis
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
To evaluate the safety profile of alfimeprase as assessed by monitoring of adverse events, serious adverse events and major bleeding events for up to 120 minutes following the instillation of study drug to an occluded central…
- Conditions
- Thrombosis, Venous Thrombosis, Catheter Occlusion
- Trial name
- NCT00322270
- Testing
- Alfimeprase
- Where
- 18 sites in United States
- Sponsor
- ARCA Biopharma, Inc.
Chronic Total Occlusion
A Single Center Study to Evaluate the Safety of the NovaCross Microcatheter in Crossing Chronic Total Occlusions
This is an open label, single-center, prospective, pivotal study in which the investigational device, NovaCross™ micro-catheter, will be tested in up to 15 patients scheduled to undergo CTO-PCI using an anterograde approach.
- Trial name
- NCT04862559
- Testing
- NovaCross
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- Nitiloop Ltd.
Stroke
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II
To explore the efficacy and safety of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes
- Trial name
- CHABLIS-T II (NCT04516993)
- Testing
- Tenecteplase, The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Huashan Hospital
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch…
- Trial name
- WAVE (NCT01710839)
- Testing
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Charles C Wykoff, PhD, MD
Stroke, Ischemic, Stroke, Acute
Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.
This study is designed to determine the efficacy and safety of Cerebrolysin treatment as an add- on therapy to mechanical thrombectomy (MT) in reducing global disability in subjects with acute ischemic stroke (AIS).
- Conditions
- Stroke, Ischemic, Stroke, Acute, Stroke Sequelae
- Trial name
- NCT04904341
- Testing
- Cerebrolysin
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Military Institute od Medicine National Research Institute
Retinal Vein Occlusion
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)
Retinal Vein Occlusion is a blockage of the blood vessels that drain out of the retina. Complications of retinal vein occlusion which threaten vision include neovascularization(growth of new blood vessels)and macular edema …
- Trial name
- NCT00211354
- Testing
- Anecortave Acetate
- Where
- United States
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Crossbite, Openbite
Implications of Pacifier Use in Israeli Children
The purpose of this study is to examine pacifier sucking habits among children, and to assess implications of the oral habit - for example malocclusions and drooling.
- Conditions
- Crossbite, Openbite, Drooling
- Trial name
- NCT01249885
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
- Trial name
- NCT02006147
- Testing
- TLC399
- Where
- 6 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Taiwan Liposome Company
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Ischemia, Retinal Vein Occlusion
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
- Conditions
- Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases
- Trial name
- RAVE2 (NCT01225146)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.